[Clinical study of cryoablation in the salvage treatment of stage III non-small cell lung cancer].
To evaluate the efficacy and safety of argon-helium cryoablation as a salvage therapy for the failure cases of non-small cell lung cancer (NSCLC) after radiochemotherapy. A total of 12 NSCLC patients (stage III) with a diagnosis of recurrence after radiochemotherapy received cryoablation. The endpoint objectives were overall response rate (RR), clinical benefit rate (CBR), 1-year survival rate, quality of life (QOL) and safety profile. Among them, the overall response rate was 6/12 cases and the clinical benefit rate 7/12 cases at 12 months post-cryoablation. The 1-year survival rate was 10/12 cases. No significant complications or adverse reactions occurred during the process of cryoablation. As shown by the QOL score, the quality of life was satisfactory. As a salvage treatment for the recurrence NSCLC cases after radiochemotherapy, cryoablation may achieve a high response rate, a favorable 1-year survival rate and a high safety profile. It has excellent prospects for clinical applications.